720 related articles for article (PubMed ID: 28630042)
41. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance.
Huang Y; Dai Z; Barbacioru C; Sadée W
Cancer Res; 2005 Aug; 65(16):7446-54. PubMed ID: 16103098
[TBL] [Abstract][Full Text] [Related]
42. xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression.
Ji X; Qian J; Rahman SMJ; Siska PJ; Zou Y; Harris BK; Hoeksema MD; Trenary IA; Heidi C; Eisenberg R; Rathmell JC; Young JD; Massion PP
Oncogene; 2018 Sep; 37(36):5007-5019. PubMed ID: 29789716
[TBL] [Abstract][Full Text] [Related]
43. Suppression of the SLC7A11/glutathione axis causes synthetic lethality in KRAS-mutant lung adenocarcinoma.
Hu K; Li K; Lv J; Feng J; Chen J; Wu H; Cheng F; Jiang W; Wang J; Pei H; Chiao PJ; Cai Z; Chen Y; Liu M; Pang X
J Clin Invest; 2020 Apr; 130(4):1752-1766. PubMed ID: 31874110
[TBL] [Abstract][Full Text] [Related]
44. Disruption of xCT inhibits cancer cell metastasis via the caveolin-1/beta-catenin pathway.
Chen RS; Song YM; Zhou ZY; Tong T; Li Y; Fu M; Guo XL; Dong LJ; He X; Qiao HX; Zhan QM; Li W
Oncogene; 2009 Jan; 28(4):599-609. PubMed ID: 19015640
[TBL] [Abstract][Full Text] [Related]
45. A negative correlation between expression profiles of runt-related transcription factor-2 and cystine/glutamate antiporter xCT subunit in ovariectomized mouse bone.
Uno K; Takarada T; Nakamura Y; Fujita H; Hinoi E; Yoneda Y
J Pharmacol Sci; 2011; 115(3):309-19. PubMed ID: 21325781
[TBL] [Abstract][Full Text] [Related]
46. Ferroptosis as a p53-mediated activity during tumour suppression.
Jiang L; Kon N; Li T; Wang SJ; Su T; Hibshoosh H; Baer R; Gu W
Nature; 2015 Apr; 520(7545):57-62. PubMed ID: 25799988
[TBL] [Abstract][Full Text] [Related]
47. NRF2 activation by cysteine as a survival mechanism for triple-negative breast cancer cells.
Bottoni L; Minetti A; Realini G; Pio E; Giustarini D; Rossi R; Rocchio C; Franci L; Salvini L; Catona O; D'Aurizio R; Rasa M; Giurisato E; Neri F; Orlandini M; Chiariello M; Galvagni F
Oncogene; 2024 May; 43(22):1701-1713. PubMed ID: 38600165
[TBL] [Abstract][Full Text] [Related]
48. Cystine/Glutamate antiporter system xc- deficiency impairs macrophage glutathione metabolism and cytokine production.
de Baat A; Meier DT; Fontana A; Böni-Schnetzler M; Donath MY
PLoS One; 2023; 18(10):e0291950. PubMed ID: 37792774
[TBL] [Abstract][Full Text] [Related]
49. Environmental cystine drives glutamine anaplerosis and sensitizes cancer cells to glutaminase inhibition.
Muir A; Danai LV; Gui DY; Waingarten CY; Lewis CA; Vander Heiden MG
Elife; 2017 Aug; 6():. PubMed ID: 28826492
[TBL] [Abstract][Full Text] [Related]
50. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
51. Increased expression of cystine/glutamate antiporter in multiple sclerosis.
Pampliega O; Domercq M; Soria FN; Villoslada P; Rodríguez-Antigüedad A; Matute C
J Neuroinflammation; 2011 Jun; 8():63. PubMed ID: 21639880
[TBL] [Abstract][Full Text] [Related]
52. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
53. Cystine-glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice.
Sprimont L; Janssen P; De Swert K; Van Bulck M; Rooman I; Gilloteaux J; Massie A; Nicaise C
Sci Rep; 2021 Jun; 11(1):12227. PubMed ID: 34108554
[TBL] [Abstract][Full Text] [Related]
54. The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer.
Jyotsana N; Ta KT; DelGiorno KE
Front Oncol; 2022; 12():858462. PubMed ID: 35280777
[TBL] [Abstract][Full Text] [Related]
55.
Chen Y; Hu S; Mu L; Zhao B; Wang M; Yang N; Bao G; Zhu C; Wu X
Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31137576
[TBL] [Abstract][Full Text] [Related]
56. Cystine/glutamate antiporter xCT deficiency reduces metastasis without impairing immune system function in breast cancer mouse models.
Ruiu R; Cossu C; Iacoviello A; Conti L; Bolli E; Ponzone L; Magri J; Rumandla A; Calautti E; Cavallo F
J Exp Clin Cancer Res; 2023 Sep; 42(1):254. PubMed ID: 37770957
[TBL] [Abstract][Full Text] [Related]
57. Reduced expression of miRNA-27a modulates cisplatin resistance in bladder cancer by targeting the cystine/glutamate exchanger SLC7A11.
Drayton RM; Dudziec E; Peter S; Bertz S; Hartmann A; Bryant HE; Catto JW
Clin Cancer Res; 2014 Apr; 20(7):1990-2000. PubMed ID: 24516043
[TBL] [Abstract][Full Text] [Related]
58. Epidermal growth factor receptor promotes glioma progression by regulating xCT and GluN2B-containing N-methyl-d-aspartate-sensitive glutamate receptor signaling.
Suina K; Tsuchihashi K; Yamasaki J; Kamenori S; Shintani S; Hirata Y; Okazaki S; Sampetrean O; Baba E; Akashi K; Mitsuishi Y; Takahashi F; Takahashi K; Saya H; Nagano O
Cancer Sci; 2018 Dec; 109(12):3874-3882. PubMed ID: 30298963
[TBL] [Abstract][Full Text] [Related]
59. NRF2 Is a Major Target of ARF in p53-Independent Tumor Suppression.
Chen D; Tavana O; Chu B; Erber L; Chen Y; Baer R; Gu W
Mol Cell; 2017 Oct; 68(1):224-232.e4. PubMed ID: 28985506
[TBL] [Abstract][Full Text] [Related]
60. Transcriptional control of cystine/glutamate transporter gene by amino acid deprivation.
Sato H; Nomura S; Maebara K; Sato K; Tamba M; Bannai S
Biochem Biophys Res Commun; 2004 Dec; 325(1):109-16. PubMed ID: 15522208
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
